8-K current report · filed Jul 14, 2026

LIGAND PHARMACEUTICALS INC (LGND) 8-K Current Report: July 14, 2026

Item 1.01Item 2.01Item 7.01Item EX-99.1Item 2.03LGND overview

Short answer

LIGAND PHARMACEUTICALS INC (LGND) filed an 8-K current report with the SEC on July 14, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.01 (Completion of Acquisition or Disposition of Assets), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item 2.03 (Creation of a Direct Financial Obligation). Merger with XOMA Royalty completed July 14, 2026, making HoldCo a wholly owned Ligand subsidiary.

LIGAND PHARMACEUTICALS INC 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • Merger with XOMA Royalty completed July 14, 2026, making HoldCo a wholly owned Ligand subsidiary
  • New $125.0 million revolving facility extends liquidity through September 12, 2028
  • Borrowings priced at Term SOFR plus 1.75%-2.50%, or base rate plus 0.75%-1.50%
  • Financial covenants include senior secured net leverage capped at 2.50x and minimum EBITDA of $100 million, rising to $150 million
  • Facility secured by company collateral, with material domestic subsidiaries providing guarantees and restrictive covenants limiting debt, investments and distributions

Item 2.01 · Completion of Acquisition or Disposition of Assets

  • Merger closed July 14, 2026, with LGND acquiring XOMA Royalty
  • XOMA Royalty common shareholders received $39.00 cash per share plus contingent value rights
  • 75% of XOMA Royalty LLC transferred to a CVR Trust, funding potential future contingent payments
  • XOMA Royalty’s 8.625% Series A and 8.375% Series B preferred stock redeemed with accrued dividends
  • Holding company reorganization separated transferred business assets and liabilities from the royalty business supporting CVR holders

Item 2.03 · Creation of a Direct Financial Obligation

  • Item 2.03 incorporates Item 1.01, indicating a potentially material financial obligation tied to the disclosed agreement
  • Investors must review Item 1.01 for obligation amount, payment terms, timing, and balance-sheet impact

Item 7.01 · Regulation FD Disclosure

  • Press release announces completion of the Merger
  • Merger closing marks transition from announced transaction to completed corporate event
  • Investors should review Exhibit 99.1 for consideration, ownership, and post-closing implications

Item EX-99.1 · Exhibit EX-99.1

  • Acquisition completed for $739 million, adding seven commercial products and over 100 development-stage assets
  • Portfolio more than doubled to over 200 royalty assets, materially broadening Ligand’s revenue base
  • Expected adjusted EPS accretion of approximately $0.50 in 2026 and $1.50 in 2027
  • XOMA Royalty shareholders received $39.00 cash per share plus CVRs tied to 75% of certain litigation net proceeds
  • XOMA Royalty shares ceased trading on Nasdaq; Ligand plans an updated five-year outlook on December 8, 2026

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other LIGAND PHARMACEUTICALS INC 8-K filings

Get the next LGND 8-K as it lands

Follow LGND for push alerts, or ask the research agent what this filing means.